Original article—alimentary tractSequential and Concomitant Therapy With Four Drugs Is Equally Effective for Eradication of H pylori Infection
Section snippets
Setting and Participants
We surveyed patients who visited the gastroenterology clinics of Kaohsiung Medical University Hospital, Kaohsiung Veteran General Hospital, and Kaohsiung Municipal Hsiao-Kang Hospital between June 2007 and May 2008.
Patients with H pylori infection were enrolled in this study. Pre-enrollment procedures included biopsy of the gastric mucosa where the presence of H pylori was assessed by histological examination of the tissue, culture, and rapid urease testing. The presence of H pylori was defined
Characteristics of the Study Groups
A total of 232 H. pylori-infected patients were randomly assigned to sequential (n = 115) or concomitant (n = 117) therapies (see Supplementary Figure 1). The first patient was randomized on February 26, 2007 and the last ended treatment on January 25, 2008. The subjects were all included in the ITT analysis for H pylori eradication. The baseline demographic and clinical characteristics of patients at entry are summarized in Table 1. The 2 groups had comparable age, gender, history of smoking,
Discussion
H pylori eradication rate following triple therapies has substantially decreased, requiring a search for novel therapeutic approaches to cure H pylori infections.16 Sequential therapy was one approach to overcoming the resistance problem, and our study showed that the administration of a PPI and 3 antibiotics, whether given sequentially or concomitantly, had good success. It also showed that there appears to be nothing special with the sequential approach, which may be more complicated than is
Acknowledgments
The authors thank Dr Claudia A. Kozinetz for the assistance with study design.
References (41)
- et al.
Eradication therapy for Helicobacter pylori
Gastroenterology
(2007) - et al.
Prevalence of antimicrobial resistance in Helicobacter pylori isolates in Taiwan in relation to consumption of antimicrobial agents
Int J Antimicrob Agents
(2009) - et al.
Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island
Am J Gastroenterol
(2002) - et al.
Antibiotic resistance problems with Helicobacter pylori
Int J Antimicrob Agents
(1999) Efficient identification and evaluation of effective Helicobacter pylori therapies
Clin Gastroenterol Hepatol
(2009)Sequential regimens for Helicobacter pylori eradication
Lancet
(2007)- et al.
Smoking increases the treatment failure for Helicobacter pylori eradication
Am J Med
(2006) Helicobacter pylori in peptic ulcer diseaseNIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease
JAMA
(1994)- et al.
Seroprevalence and associated risk factors of Helicobacter pylori infection in Taiwan
Anticancer Res
(1994) - et al.
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report
Gut
(2007)
Treatment of Helicobacter pylori
Helicobacter
Should triple therapy for Helicobacter pylori infection be abandoned as no longer effective?
US Gastroenterology
Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy
J Formos Med Assoc
The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy
Aliment Pharmacol Ther
Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication
Aliment Pharmacol Ther
Helicobacter pylori: the challenge in therapy
Helicobacter
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies
Aliment Pharmacol Ther
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study
Aliment Pharmacol Ther
Seven-day therapy for Helicobacter pylori in the United States
Aliment Pharmacol Ther
Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication
Ann Intern Med
Cited by (0)
Conflict of interest The authors disclose the following: In the last 3 years, Dr Graham has received small amounts of grant support and/or free drugs, or urea breath tests from Meretek, and BioHit for investigator-initiated and completely investigator-controlled research. Dr Graham is a consultant for Novartis in relation to vaccine development for treatment or prevention of H pylori infection. Dr Graham is a also a paid consultant for Otsuka Pharmaceuticals and until July 2007 was a member of the Board of Directors of Meretek Diagnostics, the manufacturer of the 13C-urea breath test. Dr Graham will receive royalties on the Baylor College of Medicine patent covering materials related to 13C-urea breath test until October 2009. The remaining authors disclose no conflicts.
Funding This study was funded in part by the National Science Council of the ROC (NSC-98-2314-B-037-004-MY2), Center of Excellence for Environmental Medicine, Kaohsiung Medical University and National Sun Yat-Sen University-Kaohsiung Medical University Joint Center. Role of the funding source: Funding only, no involvement in design or analysis. Dr Graham is supported in part by Public Health Service grant DK56338 which funds the Texas Medical Center Digestive Diseases Center and R01 CA116845. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the VA or NIH.